# EDGAR Filing Document

**Accession Number:** 0001807120
**File Stem:** 0000950170-25-085380
**Filing Date:** 2025-6
**Character Count:** 5662
**Document Hash:** eaf93a3c23865569f070a271c34c6f64
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-085380.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0000950170-25-085380

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250610

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Design Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001807120
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823929248
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40288
- **FILM NUMBER:** 251042773

**BUSINESS ADDRESS:**
- **STREET 1:** 6005 HIDDEN VALLEY ROAD
- **STREET 2:** SUITE 110
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92011
- **BUSINESS PHONE:** 858-293-4900

**MAIL ADDRESS:**
- **STREET 1:** 6005 HIDDEN VALLEY ROAD
- **STREET 2:** SUITE 110
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92011

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 10, 2025<br>

------

Design Therapeutics, Inc.

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40288 | 82-3929248 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 6005 Hidden Valley Road<br>Suite 110 |  |  |
| Carlsbad**,** California |  | 92011 |
| **(Address of principal executive offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (858) 293-4900<br>

N/A<br>

**(Former name or former address, if changed since last report.)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | DSGN | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 10, 2025, Design Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 15, 2025, the record date for the Annual Meeting, 56,768,678 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, where applicable, reported by rounding fractional share voting down to the nearest whole number.

*Proposal 1. Election of Directors*

The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| Heather Berger, Ph.D. | 42,402,341 | 345,797 | 10,833,440 |
| Rodney Lappe, Ph.D. | 32,799,677 | 9,948,461 | 10,833,440 |
| John Schmid | 42,289,997 | 458,141 | 10,833,440 |

---

*Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm* 

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 53,577,053 | 2,731 | 1,795 | Not applicable |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | DESIGN THERAPEUTICS, INC. |
| Date: | June 12, 2025 | By:  | /s/ Pratik Shah, Ph.D. |
|  |  |  | Pratik Shah, Ph.D.<br>President, Chief Executive Officer and Chairperson |

---

------